Bausch Health Companies Inc. (BHC.TO) TSX

Currency In CAD

AD

Bausch Health Companies Inc.

Address

2150 St. ElzEar Boulevard West

Laval, QC H7L 4A8

Canada

Phone

514-744-6792

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

20700

First IPO Date

April 03, 1996

Key Executives

NameTitlePayYear Born
Thomas J. AppioChief Executive Officer & Director5.38M1962
Aimee J. LenarExecutive Vice President of US Pharma1.82M1976
Seana CarsonExecutive Vice President & General Counsel1.86M1973
Jean-Jacques CharhonExecutive Vice President & Chief Financial Officer1.94M1965
Jonathan SadehExecutive Vice President, Chief Medical Officer and Head of R&D0N/A
Cees HeimanSenior Vice President of Europe & Canada0N/A
Garen SarafianVice President & Head of Investor Relations0N/A
Steven LeeSenior Vice President, Controller & Chief Accounting Officer01971
Jiny KimSenior Vice President of Solta Medical01978
Mirza DautbegovicExecutive Vice President & Chief Operating Officer0N/A
Kathleen FitzpatrickExecutive Vice President and Chief HR & Communications Officer0N/A
AD

Description

Bausch Health Companies Inc. is a global healthcare enterprise dedicated to the creation, production, and sale of a diverse array of pharmaceutical, medical device, and over-the-counter items. Its primary therapeutic focus areas include eye health, digestive system issues, and dermatological conditions. The company's operations are strategically organized into five key divisions: Bausch + Lomb, which specializes in vision care, surgical solutions, and ophthalmic pharmaceuticals; Salix, concentrating on gastroenterology products within the United States; International Rx, offering a broad portfolio encompassing Solta products, branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across numerous international markets in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East; Ortho Dermatologics, providing dermatological products in the U.S. and Solta medical aesthetic devices globally; and Diversified Products, covering pharmaceutical products in neurology and other therapeutic classes, alongside generic and dentistry items in the United States. Previously known as Valeant Pharmaceuticals International, Inc., the company adopted its current name in July 2018 and maintains its headquarters in Laval, Canada.

AD